
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Adaptive Biotechnologies (ADPT) Analyst Ratings
Bulls say
Adaptive Biotechnologies Corp is expected to experience a substantial growth in gross profit, driven by increases in average selling price (ASP) and improvements in sequencing margins associated with the transition to the NovaSeq X technology. The company's financial position related to minimal residual disease (MRD) diagnostics is forecasted to enhance further in 2025, supported by incremental volume growth and ASP improvements contributing to revenue uplift. Additionally, the 17% increase in episode pricing is anticipated to catalyze ASPs nearing the longer-term target of exceeding $1,300, positioning the company for continued financial advancement.
Bears say
The financial outlook for Adaptive Biotechnologies Corp suggests a stagnation in Immune Medicine revenue, with expectations of flat growth due to ongoing efforts to generate interest in their TCR-Antigen model and develop their autoimmunity program. Additionally, a significant challenge is highlighted by the fact that approximately 25% of patients receiving an ID test do not go on to receive an MRD test within a year, negatively impacting the average test frequency and potential revenue. Despite holding a leadership position in the market, these factors contribute to an overall negative financial forecast for the company.
This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.
Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction
Start investing in Adaptive Biotechnologies (ADPT)
Order type
Buy in
Order amount
Est. shares
0 shares